Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement
Advertisement

FDA Grants Fast Track Designation to Sapanisertib in Treatment of Squamous Lung Cancer

By: JNCCN 360 Staff
Posted: Friday, October 7, 2022

On October 3, Calithera Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational mTORC1/2 inhibitor sapanisertib (CB-228) for the treatment of adults with unresectable or metastatic squamous non–small cell lung cancer (NSCLC) that harbors a mutation in NRF2. Eligible patients have received prior platinum-based chemotherapy and immune checkpoint inhibitor therapy.

NRF2 mutations are found across multiple solid tumors, with these mutations occurring in approximately 15% of patients with squamous NSCLC. Sapanisertib targets a survival mechanism in NRF2-mutated tumor cells.

A recent investigator-initiated, multicenter, open-label phase II trial (ClinicalTrials.gov identifier NCT05275673) is evaluating sapanisertib monotherapy in patients with NRF2-mutated squamous NSCLC whose disease has progressed on or after platinum-doublet chemotherapy and immune checkpoint inhibitor therapy (anti–PD-L1) with or without anti–CTLA-4. Sapanisertib is being given in a dose schedule of 2 mg twice a day or 3 mg once a day in those with either wild-type or mutated NRF2, as detected by next-generation sequencing.

According to the manufacturer, use of sapanisertib has been well tolerated and demonstrated single-agent activity. The confirmed overall response rate in the phase II trial was 27% (3 of 11 patients), and median progression-free survival was 8.9 months (95% confidence interval = 7 months to not reached) in heavily pretreated patients with NRF2-mutated squamous NSCLC.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.